Remove tag access-medicines
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The challenge of providing adequate access to the peripheral EU markets is quite evident. Europe’s forgotten territories.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Marketing 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

Areas including trial enrollment or Managed Access Programs, coordination with Patient Advocacy Groups to imbibe patient input into treatment development, product access post-launch, and RWE support for added indications will become the mainstay for Medical Affairs as we move ahead.

Medical 52
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. We have the emergence of this new pillar of medicine, which is out of the lab and beyond clinical trials now. AZ: What is the ISCT doing to tackle supply and access-related obstacles in the CAR-T field?

article thumbnail

Rare Disease Spotlight – tracing the rise of orphan drug designations over almost 40 years

Pharmaceutical Technology

Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications.

article thumbnail

You can’t afford to get cancer

World of DTC Marketing

As cancer survival rates rise, so do the price tags of life-saving treatments. Cardio procedures and medicines are well established, and a big part of the solution is lifestyle changes — eating well, exercising, and reducing stress. OPENING: American cancer patients spent more than $21 billion on their care in 2019.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.